Among thousands of patients treated at a large network of U.S. academic medical clinics, most had kept the weight off or lost even more 18 months after stopping semaglutide, sold by Novo Nordisk as ...

Real-world data suggests weight loss durability post-GLP-1 drug discontinuation Study suggests weight regain may be less common than clinical trial extensions indicate Behavioral changes may aid ...

The "Deep Learning Market in Drug Discovery and Diagnostics - Industry Trends and Global Forecasts to 2035: By Therapeutic Areas and Key Geographical Regions" report has been added to ...

Aiolos Bio Inc. and its founders, Dr. Anthony P. Adamis and Khurem Farooq, filed a declaratory judgment action against nference Inc. on Oct. 6 in the Delaware Court of Chancery, seeking to enforce a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An asthma drug biotech that was ...

NEW YORK – nFerence on Thursday said it has partnered with BeiGene to study treatment patterns and outcomes in B-cell cancers using nFerence's Agentic artificial-intelligence platform. Agentic AI is a ...

-- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing ...